Aro Biotherapeutics

Philadelphia, PA · Founded 2018 · Privately Held (backing)

Developer of a protein drug platform designed to unlock the potential of genetic medicines. Aro Biotherapeutics is based in Philadelphia, PA and was founded in 2018. It was valued at $182 million at its later-stage round in Nov 2023, the last priced event on record. It has raised $132 million across 4 recorded rounds; the latest was a $24 million early-stage round in Dec 2022.

PMV mark · valuation
$181.5M
Oct 2026
Priced at
its later-stage round
Nov 2023
Total raised
$131.8M
Last round
Early Stage VC
Dec 2022
What is Aro Biotherapeutics worth?
$181.5MPrivateMarketView mark · Oct 2026

Valued at $181.5M at its later-stage round, Nov 2023. Nothing has traded since.

Free account
More of Aro Biotherapeutics with a free account
  • ·Watch Aro Biotherapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Aro Biotherapeutics funding history

4 rounds
DateRoundRaisedPost-money
Dec 2022Early Stage VC$24.0M▮
Dec 2020Later Stage VC$90.3M▮
Dec 2019Early Stage VC$5.0M▮
Mar 2019Seed Round$3.5M▮
Unlock post-money valuations

Membership and data by Private Market View

Aro Biotherapeutics valuation

Aro Biotherapeutics was valued at $182 million at its later-stage round in Nov 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Aro Biotherapeutics raised?

Aro Biotherapeutics has raised $132 million across 4 recorded rounds since 2019. The largest was a $90.3 million later-stage round in Dec 2020; the most recent was a $24 million early-stage round in Dec 2022.

Aro Biotherapeutics has filed 7 Form Ds with the SEC since 2019, most recently in Dec 2022 ($24 million sold to 12 investors).

How Aro Biotherapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Aro Biotherapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Aro Biotherapeutics

What is Aro Biotherapeutics worth?
Aro Biotherapeutics is valued at $181.5M as of Oct 2026. Valued at $181.5M at its later-stage round, Nov 2023. Nothing has traded since.
How much has Aro Biotherapeutics raised?
Aro Biotherapeutics has raised $131.8M in total funding across 4 recorded rounds.
When did Aro Biotherapeutics last raise?
Aro Biotherapeutics last raised in Dec 2022 (Early Stage VC), raising $24.0M.